Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression

Yu,Muming; Lu,Bin; Liu,Yancun; Me,Ying; Wang,Lijun; Zhang,Peng

doi:10.3892/mmr.2016.6065

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression

Authors:
- Muming Yu
- Bin Lu
- Yancun Liu
- Ying Me
- Lijun Wang
- Peng Zhang
View Affiliations

Affiliations: Department of Emergency, Tianjin Medical University General Hospital, Tianjin 300071, P.R. China, School of Basic Medical Sciences, Medical Institution of Peking University, Beijing 100191, P.R. China
Published online on: December 22, 2016 https://doi.org/10.3892/mmr.2016.6065
Pages: 689-695
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

T cell immunoglobulin mucin-3 (Tim-3) has previously been implicated in the immune response and tumor biology. Colorectal carcinoma (CRC) is a malignancy, which is closely associated with inflammation. However, the role of Tim‑3 in the progression of CRC remains to be fully elucidated. The present study aimed to investigate the role of Tim‑3 in the progressive activities of human CRC. A total of 30 clinical CRC tissues and their adjacent tissues were collected. Slides from another 112 cases that underwent CRC surgical resection were also obtained. The protein and mRNA levels of Tim‑3 in the clinical tissues and in CRC cell lines were initially examined using western blot and reverse transcription‑quantitative polymerase chain reaction analyses, respectively. Immunohistochemical staining was performed to detect Tim‑3 in the CRC samples. Specific small interfering (si)RNA against Tim‑3 (siTim‑3) was synthesized to knock down the expression of Tim‑3, and the subsequent effects of Tim‑3 knockdown on cell proliferation, migration and invasion were assessed. The data obtained showed that Tim‑3 was expressed at high levels in the CRC tissues, compared with the non‑cancerous tissues. The expression of Tim‑3 in the clinical tissues was significantly associated with tumor size (P=0.007), tumor‑node‑metastasis staging (P<0.0001) and distant metastasis (P<0.0001). Knockdown of Tim‑3 significantly reduced the cell proliferative rate of HCT116 and HT‑29 cells. Wound closure activity was also inhibited by knockdown of Tim‑3 in these two cell lines, and the migration and invasive abilities of these two cell lines were consistently decreased following knockdown of Tim‑3. Taken together, Tim‑3 was found to be a critical mediator in the progression of CRC and may serve as a potential therapeutic target for the treatment of CRC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F, Xu L, Ye M and Duan S: Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol. 8:1992013. View Article : Google Scholar : PubMed/NCBI
3	Qu YL, Wang HF, Sun ZQ, Tang Y, Han XN, Yu XB and Liu K: Up-regulated miR-155-5p promotes cell proliferation, invasion and metastasis in colorectal carcinoma. Int J Clin Exp Pathol. 8:6988–6994. 2015.PubMed/NCBI
4	Diakos CI, Charles KA, McMillan DC and Clarke SJ: Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 15:e493–e503. 2014. View Article : Google Scholar : PubMed/NCBI
5	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI
6	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
7	Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, Maguire C, Hind D and Tappenden P: Chemoprevention of colorectal cancer: Systematic review and economic evaluation. Health Technol Assess. 14:1–206. 2010. View Article : Google Scholar
8	Goh CH, Leong WQ, Chew MH, Pan YS, Tony LK, Chew L, Tan IB, Toh HC, Tang CL, Fu WP and Chia WK: Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I–III colorectal cancer. Anticancer Res. 34:7407–7414. 2014.PubMed/NCBI
9	Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 353:2654–2666. 2005. View Article : Google Scholar : PubMed/NCBI
10	Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F and Galon J: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 29:610–618. 2011. View Article : Google Scholar : PubMed/NCBI
11	Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG and McArdle CS: Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer. 90:1707–1709. 2004.PubMed/NCBI
12	Guthrie GJ, Roxburgh CS, Farhan-Alanie OM, Horgan PG and McMillan DC: Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer. 109:24–28. 2013. View Article : Google Scholar : PubMed/NCBI
13	Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ and Kuchroo VK: Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 4:1102–1110. 2003. View Article : Google Scholar : PubMed/NCBI
14	Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 415:536–541. 2002. View Article : Google Scholar : PubMed/NCBI
15	Horlad H, Ohnishi K, Ma C, Fujiwara Y, Niino D, Ohshima K, Jinushi M, Matsuoka M, Takeya M and Komohara Y: TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma. Oncol Lett. 12:1519–1524. 2016.PubMed/NCBI
16	Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, Deng L, Wang Y, Zhang X, Jiang T and Lu X: Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines. J Immunother. 39:171–180. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kuchroo VK, Umetsu DT, DeKruyff RH and Freeman GJ: The TIM gene family: Emerging roles in immunity and disease. Nat Rev Immunol. 3:454–462. 2003. View Article : Google Scholar : PubMed/NCBI
18	Piao YR, Piao LZ, Zhu LH, Jin ZH and Dong XZ: Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer. Asian Pac J Cancer Prev. 14:3897–3901. 2013. View Article : Google Scholar : PubMed/NCBI
19	Piao YR, Jin ZH, Yuan KC and Jin XS: Analysis of Tim-3 as a therapeutic target in prostate cancer. Tumour Biol. 35:11409–11414. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zheng H, Guo X, Tian Q, Li H and Zhu Y: Distinct role of Tim-3 in systemic lupus erythematosus and clear cell renal cell carcinoma. Int J Clin Exp Med. 8:7029–7038. 2015.PubMed/NCBI
21	Ngiow SF, Teng MW and Smyth MJ: Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 71:6567–6571. 2011. View Article : Google Scholar : PubMed/NCBI
22	Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, Gorbe E, Papp Z and Falus A: TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol. 127:906–914. 2007. View Article : Google Scholar : PubMed/NCBI
23	Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, Liang X and Ma C: Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages. Gut. 64:1593–1604. 2015. View Article : Google Scholar : PubMed/NCBI
24	Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
25	Chono H, Saito N, Tsuda H, Shibata H, Ageyama N, Terao K, Yasutomi Y, Mineno J and Kato I: In vivo safety and persistence of endoribonuclease gene-transduced CD4+ T cells in cynomolgus macaques for HIV-1 gene therapy model. PLoS One. 6:e235852011. View Article : Google Scholar : PubMed/NCBI
26	Smolle MA, Pichler M, Haybaeck J and Gerger A: Genetic markers of recurrence in colorectal cancer. Pharmacogenomics. 16:1315–1328. 2015. View Article : Google Scholar : PubMed/NCBI
27	Kim MJ, Lee WY and Choe YH: Expression of TIM-3, human β-defensin-2, and FOXP3 and correlation with disease activity in pediatric crohn's disease with infliximab therapy. Gut Liver. 9:370–380. 2015.PubMed/NCBI
28	Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, et al: MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology. 58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
29	Yun UJ, Park SE, Jo YS, Kim J and Shin DY: DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. Cancer Lett. 323:155–160. 2012. View Article : Google Scholar : PubMed/NCBI